Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 49,700 shares, a growth of 21.8% from the July 15th total of 40,800 shares. Currently, 5.7% of the shares of the company are sold short. Based on an average daily trading volume, of 51,500 shares, the days-to-cover ratio is currently 1.0 days.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics as of its most recent filing with the SEC. Institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Price Performance

Shares of NASDAQ ATXI traded down $0.08 during trading hours on Friday, hitting $2.50. 23,223 shares of the stock were exchanged, compared to its average volume of 66,896. The firm has a market capitalization of $2.35 million, a P/E ratio of -0.32 and a beta of -0.19. Avenue Therapeutics has a one year low of $2.25 and a one year high of $77.25. The company’s 50 day moving average is $3.18 and its 200 day moving average is $6.82.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.